However, although multiple series evaluating NPM1-mutated MRD also enrolled some patients aged >60 years (Table 1) [31,32,33,34,35,36,37,39,42,43,44,45,47,48,49,50,51,52,53,54,55,56,58,60,61,62,63,65,67,69,71], no study so far specifically focused on application and clinical significance of MRD monitoring in elderly patients with NPM1-mutated AML. Here, NPM1 is linked to acute myeloid leukemia.